Arnold & Porter Blog

At Arnold & Porter, we prioritize our clients and focus on their industries. Our attorneys specialize in over 40 different areas, spanning litigation, regulation, and transactions, to assist clients with intricate requirements. We help them stay competitive in the global market, identify new opportunities, and tackle challenges that can affect their business's value. With our extensive global presence, experience, and in-depth understanding, we are equipped to navigate various geographic, cultural, technological, and ideological boundaries. This enables us to provide clients with innovative, results-driven solutions for their legal needs, whether they are domestic, international, or cross-border.

International

English

Blog

Outlet metrics

Domain Authority

Ranking

Global

#269879

United States

#69029

Law and Government/Legal

#367

Traffic sources

Monthly visitors

Articles

Federal Banking Agencies Clarify Approach to Bank-Permissible Crypto-Asset Activities | Advisories | Arnold & Porter

1 month ago | arnoldporter.com

Arnold & Porter
China Introduces a New Regulatory Data Protection and Exclusivity Mechanism

1 month ago | arnoldporter.com | Andrew Chen |John Tan |Alex Wang |Siyi Gu

On March 19, 2025, China’s National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection (the Draft Measures) for public comment, due by May 18, 2025.1 The Draft Measures, together with China’s regulatory schemes for patent linkage and market exclusivity, are a significant development in China’s regulatory data exclusivity protection and demonstrate Chinese regulators’ commitment to aligning with...
Impact of Trump Administration Directives on Scientific Research in the U.S. | Advisories | Arnold & Porter

Mar 3, 2025 | arnoldporter.com

Arnold & Porter
SEC’s Division of Corporation Finance Issues SLB 14M, Rescinding SLB 14L

Feb 27, 2025 | arnoldporter.com | Sara Adler |Joel Greenberg

On February 12, 2025, the SEC’s Division of Corporation Finance (Division) issued Staff Legal Bulletin (SLB) No. 14M.1SLB 14M provides guidance on the scope and application of Exchange Act Rules 14a-8(i)(5) and 14a-8(i)(7), which set forth two of the 13 bases upon which companies may exclude shareholder proposals from their proxy materials, as well as other aspects of the rules governing shareholder proposals.
What Banking Organizations Need to Know About the Trump Executive Orders

Jan 31, 2025 | arnoldporter.com | Richard Alexander |Robert Azarow |James Bergin |David Freeman

Since taking office on January 20, 2025, President Donald J. Trump has signed a staggering number of Executive Orders 1 and Memoranda,2 and more continue to be issued each day. These executive actions signal President Trump’s aggressive agenda to significantly redefine federal policy in a range of areas.
The Trump AI Executive Order: Takeaways for Developers and Deployers

Jan 29, 2025 | arnoldporter.com | Peter J. Schildkraut |Thomas A. Magnani |Raqiyyah Pippins

In his first week back in office, President Trump both rescinded President Biden’s artificial intelligence (AI) Executive Order (EO; see our analysis of the Biden AI EO) and issued a short AI Executive Order of his own.
Commerce Department Imposes Sweeping Global Restrictions on AI Technologies

Jan 27, 2025 | arnoldporter.com | John Barker |Charles Blanchard |Ronald Lee |Soo-Mi Rhee

On January 15 and 16, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) published two interim final rules (IFR) aimed at reducing the risk that countries of concern obtain the most advanced artificial intelligence (AI) models and advanced computing items. The first IFR is known as the Framework for AI Diffusion and may be referred to as the Diffusion rule. The second IFR may be referred to as the Presumption rule.
China Life Sciences: 2024 Year in Review

Jan 24, 2025 | arnoldporter.com | Andrew Chen |John Tan |Alex Wang |Siyi Gu

The life sciences industry remained a primary focus for Chinese regulators in 2024. Key developments such as China’s first draft law regulating the medical device industry, the Medical Device Administration Law (《中华人民共和国医疗器械管理法（草案征求意见稿）》), and the Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (《医药企业防范商业贿赂风险合规指引》) marked milestones in the development of China’s regulatory framework for the industry.
Trump Administration Rescinds Certain Equal Employment-Related Executive Orders and Prohibits “DEI” | Advisories | Arnold & Porter

Jan 24, 2025 | arnoldporter.com

Arnold & Porter
AI and the Future of Corporate Compliance

Jan 16, 2025 | arnoldporter.com | Andre Geverola

Artificial intelligence is shaping the future of corporate compliance. What impact does new technology have on how companies assess and monitor their risks? In our latest Critical Compliance video, Arnold & Porter partner Andre Geverola breaks down the Department of Justice's recent updates to compliance guidance, which highlight the crucial role of AI in corporate oversight. Watch the rest of the Critical Compliance series here.